drugset / Trial / NCT04728698
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19 infection in hospitalized subjects with ARD/ARDS.
Timeline
- Start
- 2021-03
- Primary completion
- 2021-09
- Completion
- 2021-09
Outcome
Outcome not reported
Stopped: “Replaced by a different protocol.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVI-MSC | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | COVI-MSC | Cell therapy | 1.5e+06 cells/kg | Intravenous |